• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

ALKS:US

48.3300 USD 0.5300 1.11%

As of 15:18:52 ET on 07/11/2014.

Snapshot for Alkermes PLC (ALKS)

Open: 47.7700 Day's Range: 47.2600 - 48.4500 Volume: 304,560
Previous Close: 47.8000 52wk Range: 28.8600 - 54.2500 1-Yr Rtn: +60.72%

Stock Chart for ALKS

No chart data available.
  • ALKS:US 48.3600
  • 1D
  • 1M
  • 1Y
47.8000
Interactive ALKS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ALKS

Current P/E Ratio (ttm) 921.8223
Estimated P/E(12/2014) 95.2756
Relative P/E vs. SPX 51.2571
Earnings Per Share (USD) (ttm) 0.0525
Est. EPS (USD) (12/2014) 0.5080
Est. PEG Ratio 4.1245
Market Cap (M USD) 6,991.64
Shares Outstanding (M) 144.52
30 Day Average Volume 717,475
Price/Book (mrq) 5.2149
Price/Sale (ttm) 11.8191
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/25/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ALKS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ALKS

Alkermes PLC researches pharmaceuticals. The Company develops treatments for central nervous system disorders such as addiction, schizophrenia and depression, and diabetes.

Richard F PopsChairman/CEOShane CookePresident
James M Frates "Jim"Senior VP/CFO/TreasurerGordon G PughSenior VP/COO/Chief Risk Ofcr
More Company Profile & Key Executives for ALKS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil